An expedited multimodal cardiac imaging approach is warranted when this rare cardiotoxicity is suspected.

Chemotherapy-related cardiac dysfunction during pregnancy demands vigilant cardiac surveillance, tailored therapy during pregnancy, and precise labor and delivery planning by a multidisciplinary team to optimize maternal and fetal outcomes.

P1, N=16, Active, not recruiting, Byondis B.V. | Recruiting --> Active, not recruiting | N=100 --> 16 | Trial completion date: Mar 2027 --> Feb 2026 | Trial primary completion date: Dec 2026 --> Sep 2025

During this period, she received escalating immunosuppression with corticosteroids, mycophenolate, and cyclophosphamide...Immunosuppression was de-escalated to hydroxychloroquine alone with no recurrence at 14-month follow-up...Cardiac myxomas produce IL-6 in the majority of patients (frequency >75%), and systemic constitutional signs are observed in a substantial proportion, though not uniformly. This can produce IL-6-mediated inflammation indistinguishable from autoimmune flares.

Further analysis revealed that DHM increased the activity of Na+-K+-ATPase in mice, which affected CTX-induced mitochondrial energy metabolism. To conclude, DHM protected against CTX-induced hepatotoxicity, possibly through reducing oxidative stress and regulating energy metabolism, providing a potential strategy for treatment and prevention.

Cyclophosphamide and BCc1 nanomedicine exhibited distinct regulatory effects on autophagy-associated genes...The observed gene expression profile-characterized by mTOR suppression and Beclin-1 upregulation alongside reduced ATG-4B and ATG-7 expression-indicates a selective enhancement of autophagy initiation, coupled with alterations in autophagosome maturation. This nuanced modulation of autophagy may contribute to BCc1's anti-tumor activity and warrants further investigation into its stage-specific mechanistic effects in cancer therapy.

Postoperatively, the patient received TC(docetaxel+cyclophosphamide) chemotherapy, total breast irradiation, and tamoxifen for 10 years. Considering the different subtypes and absence of other lesions, the patient was considered to have latent breast cancer as a new lesion. Chemotherapy, including anti- HER2 therapy, radiotherapy, and endocrine therapy, was administered as adjuvant treatment.

Following completion of weekly paclitaxel(PTX), initiation of epirubicin plus cyclophosphamide(EC)resulted in a marked platelet decrease to 1.3×104/μL on day 7, necessitating repeated platelet transfusions. These findings suggest that in breast cancer patients with ITP, neoadjuvant chemotherapy may not be feasible, and primary surgical intervention should be considered. Furthermore, when administering EC, vigilant hematological monitoring is imperative.

P1, N=36, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

The quality and health of these embryos, measured by their development and important growth markers, were also similar. These findings provide hopeful news for young girls who receive certain types of chemotherapy, who may still have the option to use IVF in the future without increased risk of embryo damage during freezing.

Here, we investigated the therapeutic potential of indomethacin (Indo), a prototypical NSAID, in combination with cyclophosphamide (CTX), a widely used chemotherapeutic agent with immunostimulatory properties. Importantly, Indo retained therapeutic benefit following CTX even in tumors incapable of producing PGE₂, demonstrating a critical contribution of COX-independent mechanisms, particularly inhibition of tumor-intrinsic oncogenic RAS signaling, to the enhanced efficacy of the CTX+Indo combination. Collectively, our results provide strong preclinical rationale for leveraging the COX/PGE 2 and RAS dual inhibitory capacities of NSAIDs to enhance the efficacy of chemotherapy and immunotherapy.

B-cell chronic lymphocytic leukemia (B-CLL) was diagnosed, which in cats is much less frequent than T-CLL. There was a favorable response to alkylating therapy, and the cat survived for 19 months.